News

Repros Therapeutics, a developer of oral small molecule drugs, has reported net loss of $5.86m or $0.39 per share, for the three-month period ended December 31, 2008, compared

Synta Pharmaceuticals, a biopharmaceutical company, has reduced its workforce by approximately 90 positions, to a total of approximately 130 positions, allowing the company to operate with current cash

The company recorded a loss of C$6.57 million, or C$0.13 per share, for the six-month period ended January 31, 2009, compared to a loss of C$3.17 million, or

Net loss for the year ended December 31, 2008, was $9.13 million, or $0.38 per share, compared with a net loss of $7.28 million, or $0.31 per share,

According to Intradigm, the allowed subject matter covers a specific double-stranded small interfering RNA (siRNA) sequence that is directed against the angiogenic pathway and which possesses therapeutic potential

St Jude Medical, a medical device company, has received the FDA’s approval for its newest version of the Merlin.net Patient Care Network, an internet-based remote care system for

The company has partnered with Nobel Ilac for Turkey, PharmaSwiss for Israel and Adcock Ingram for South Africa for commercializing the product, subject to regulatory review and approval,

Net loss for the year ended December 31, 2008 was $6.08 million, or $0.07 per share, compared to a net loss of $3.45 million, or $0.04 per share,

For the 12 months ended December 31, 2008, net loss attributable to common stockholders was $81.25 million, or $3.25 per share, compared to a net loss attributable to